AVAH vs USPH

Key Takeaways

• AVAH has delivered a dramatic financial turnaround, with full-year 2025 revenue reaching $2.43 billion (up 20.2% year-over-year) and Adjusted EBITDA surging 74.8% to $320.8 million.
• USPH operates a more mature, steady-state business model, generating $95.0 million in Adjusted EBITDA for 2025, up 16.2%, supported by record patient visit volumes and a growing industrial injury prevention segment.
• AVAH trades at a trailing P/E (price-to-earnings) ratio of approximately 8.2, reflecting its recent return to profitability, while USPH carries a significantly higher trailing P/E near 158, distorted by non-cash charges related to redeemable noncontrolling interests.
• Both companies are active acquirers in their respective healthcare niches, but AVAH's acquisition strategy (Thrive Skilled Pediatric Care, Family First Homecare) has been a primary growth engine, whereas USPH relies on a mix of tuck-in clinic acquisitions and strategic hospital alliances.
• USPH pays a quarterly dividend ($0.46 per share, yielding approximately 2.3%), making it more attractive to income-oriented investors; AVAH pays no dividend, reinvesting all capital into growth and deleveraging.
• Market sentiment has favored AVAH over the trailing twelve months, with the stock up more than 140%, compared to USPH's modest single-digit annual gain.

Introduction

Investors scanning the healthcare services landscape often encounter two distinctly different value propositions: the high-growth, turnaround-driven home care platform and the steady, dividend-paying outpatient therapy operator. This comparison between AVAH (Aveanna Healthcare Holdings Inc.) and USPH (U.S. Physical Therapy, Inc.) illuminates those contrasts. Both companies operate within the broader patient-care ecosystem, yet their business models, growth trajectories, capital allocation strategies, and risk profiles diverge meaningfully. For traders weighing momentum against stability — and for long-term investors evaluating risk-adjusted return potential — understanding how these two names stack up against each other is timely and relevant.

AVAH Overview and Recent Performance

Aveanna Healthcare Holdings is a diversified home care platform headquartered in Atlanta, Georgia, focused on serving medically complex, high-cost patient populations across the United States. The company operates through three segments: Private Duty Services (PDS), which accounts for roughly 78% of revenue and provides skilled nursing to pediatric and adult patients in their homes; Home Health and Hospice (HHH); and Medical Solutions (MS).

In recent quarters, AVAH has executed what can fairly be described as a significant operational turnaround. After posting net losses through much of 2023 and 2024, the company achieved profitability and sustained momentum throughout 2025. Full-year 2025 revenue reached $2.43 billion, representing 20.2% growth over the prior year, while Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization, a measure of operating profitability) climbed to $320.8 million — a 74.8% increase. The fourth quarter alone produced revenue of $662.5 million and Adjusted EBITDA of $85.0 million.

Several catalysts have supported this performance. The integration of Thrive Skilled Pediatric Care, a major acquisition, expanded AVAH's footprint and was completed on schedule. The company expanded its preferred payer agreements from 22 to 30 during 2025, strengthening reimbursement dynamics. A successful debt refinancing extended maturities and improved terms. On the acquisition front, AVAH announced in March 2026 the planned purchase of Family First Homecare for $175.5 million, which is expected to close in the second quarter and add complementary pediatric home care capacity across seven states. The stock has reflected this momentum, trading near its 52-week highs in recent weeks with a market capitalization of approximately $2.1 billion.

USPH Overview and Recent Performance

U.S. Physical Therapy, Inc., based in Houston, Texas, operates a national network of outpatient physical therapy clinics alongside an industrial injury prevention (IIP) services business. As of year-end 2025, the company managed 780 clinics across the country. The IIP segment provides on-site injury prevention, ergonomic assessments, and wellness programs for employers in manufacturing, distribution, government, and other sectors.

USPH's 2025 financial results reflect a business in steady expansion rather than rapid transformation. Full-year Adjusted EBITDA reached $95.0 million, a 16.2% increase from $81.8 million in 2024. Physical therapy operations generated consistent revenue growth, with the fourth quarter delivering net patient revenue of $173.8 million, up 13.0% year-over-year. Total patient visits for the full year exceeded 6.1 million, with average daily visits per clinic hitting record levels in multiple quarters. The IIP segment contributed $28.9 million in fourth-quarter revenue, up 8.7%.

Notably, USPH has pursued strategic hospital alliances as a growth avenue, announcing in early 2026 two separate 10-year agreements: one involving 60 clinics through its MSO Metro subsidiary partnering with a major New York hospital system, and another covering 10 clinics with a local hospital partner. These alliances aim to embed USPH's clinic networks within larger healthcare systems, potentially enhancing patient referrals and reimbursement stability. The company also raised its quarterly dividend from $0.45 to $0.46 per share, extended its share repurchase program, and issued 2026 Adjusted EBITDA guidance of $102 million to $106 million. With a market capitalization near $1.2 billion, USPH trades well below its 52-week high of $93.50 reached in late 2025.

Trending AI Robots

For traders seeking a data-driven edge in navigating stocks like AVAH and USPH, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers across multiple strategies and timeframes, but only the top performers — those best aligned with the current market environment — earn placement in the Trending AI Robots section. These bots span a wide range of trading styles, from swing trading and trend following to mean-reversion and breakout strategies, with performance statistics that can include annualized returns ranging from modest single digits to well into double-digit territory, depending on risk parameters and market conditions. Each bot comes with its own track record, win rate, and trade history, allowing users to evaluate its suitability. Exploring the Trending AI Robots page can help investors identify automated strategies that match their risk tolerance and market outlook.

Head-to-Head Comparison

While both AVAH and USPH operate in patient-facing healthcare services, their business models diverge sharply on several dimensions.

Growth Profile: AVAH is in the midst of a multi-year strategic transformation that has produced outsized revenue and EBITDA growth. The company's expansion is fueled by M&A (mergers and acquisitions), organic volume gains, and improved payer reimbursement rates. USPH, by contrast, generates more measured growth. Its mature clinics posted near-flat revenue in recent quarters, meaning most top-line expansion comes from acquiring new clinics or adding ancillary services like home-care visits and IIP contracts. USPH's growth is steadier but slower.

Profitability and Margins: AVAH reported a consolidated gross margin of approximately 32% in recent quarters, with Adjusted EBITDA margins expanding toward 13%. USPH's physical therapy operations generated adjusted gross margins in the 18-19% range, reflecting the labor-intensive nature of outpatient therapy. However, USPH operates with significantly less financial leverage — AVAH carries roughly $1.49 billion in total debt versus USPH's more conservative balance sheet.

Market Sentiment and Valuation: AVAH has been a momentum favorite, delivering a 142% return over the past twelve months. Its trailing P/E of roughly 8.2 appears inexpensive but must be weighed against elevated debt and ongoing integration risk. USPH's trailing P/E near 158 is heavily distorted by non-cash accounting adjustments tied to redeemable noncontrolling interests; on a forward basis, the P/E compresses to roughly 29, and the stock offers a 2.3% dividend yield. USPH has underperformed AVAH dramatically over the past year but offers a more predictable earnings stream.

Risk Factors: AVAH's primary risks include high financial leverage, exposure to state-level Medicaid budget decisions that can affect reimbursement rates, and integration risk associated with serial acquisitions. Labor availability for caregivers remains a persistent operational challenge. USPH faces Medicare reimbursement pressure — a cumulative estimated $20 million profit impact from rate cuts between 2021 and 2025 — and the structural headwind of mature clinics generating minimal organic growth. Both companies are exposed to regulatory changes in healthcare funding, though through different government programs.

Tickeron AI Verdict

Based on observable trend consistency, relative momentum, and the magnitude of operational improvement, Tickeron's AI would likely favor AVAH over USPH in the current market environment. AVAH's combination of accelerating revenue growth, dramatic EBITDA expansion, successful acquisition integration, and upwardly revised guidance forms a coherent bullish narrative that quantitative trend-following models tend to reward. USPH's steadier, dividend-supported profile may appeal to risk-averse algorithms focused on capital preservation, but the stock's lower momentum readings and flatter mature-clinic trends reduce its relative appeal in a head-to-head growth comparison. That said, this assessment reflects probabilistic analysis of current conditions — it is not a prediction of future price action, and market dynamics can shift as new data emerges.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations